Finoriq research workspace
Caris Life Sciences, Inc. (CAI) Company Overview
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling. Review CAI filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
- Company
- Caris Life Sciences, Inc. (CAI)
- Ticker
- CAI
- Market Cap
- $4.4B
- Latest Price
- $15.58
- Industry
- Medical Devices
Caris Life Sciences, Inc. (CAI) Current Valuation Metrics
Static valuation preview for Caris Life Sciences, Inc. (CAI). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 5.92x | Revenue | TTM FY 2025 |
| P/Operating Cash FlowMarket cap divided by latest TTM operating cash flow. | 57.8x | Operating Cash Flow | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | -1.4% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | 1.7% | Operating Cash Flow | TTM FY 2025 |
| Price / BookMarket cap divided by stockholders' equity. | 8.33x | Stockholders' Equity | FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.